

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM399737

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
BIOCRYST PHARMACEUTICALS, INC.		09/23/2016	Corporation: DELAWARE
MDCP, LLC		09/23/2016	Limited Liability Company: DELAWARE

RECEIVING PARTY DATA

Name:	MIDCAP FINANCIAL TRUST, AS AGENT
Street Address:	7255 Woodmont Avenue, Suite 200
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20814
Entity Type:	Statutory Trust: DELAWARE

PROPERTY NUMBERS Total: 7

Property Type	Number	Word Mark
Serial Number:	86461211	
Registration Number:	3974837	BIOCRYST
Registration Number:	4096431	BIOCRYST
Registration Number:	3966596	
Registration Number:	2902002	BIOCRYST PHARMACEUTICALS, INC.
Registration Number:	3974836	BIOCRYST PHARMACEUTICALS, INC.
Registration Number:	4074214	DESIGN. OPTIMIZE. DELIVER.

CORRESPONDENCE DATA

Fax Number: 7036106200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7036106100

Email: boxip@hoganlovells.com

Correspondent Name: Valerie Brennan, Hogan Lovells US LLP

Address Line 1: 7930 Jones Branch Drive, 9th Floor

Address Line 2: Attn: Box Intellectual Property

Address Line 4: McLean, VIRGINIA 22102

OP \$190.00 86461211

NAME OF SUBMITTER:	Valerie Brennan
SIGNATURE:	/vb/
DATE SIGNED:	09/26/2016
Total Attachments: 16 source=IP Security Agreement#page1.tif source=IP Security Agreement#page2.tif source=IP Security Agreement#page3.tif source=IP Security Agreement#page4.tif source=IP Security Agreement#page5.tif source=IP Security Agreement#page6.tif source=IP Security Agreement#page7.tif source=IP Security Agreement#page8.tif source=IP Security Agreement#page9.tif source=IP Security Agreement#page10.tif source=IP Security Agreement#page11.tif source=IP Security Agreement#page12.tif source=IP Security Agreement#page13.tif source=IP Security Agreement#page14.tif source=IP Security Agreement#page15.tif source=IP Security Agreement#page16.tif	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the 23 day of September, 2016 by and between **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust (“Agent”) and **BIOCRYS T PHARMACEUTICALS, INC.**, a Delaware corporation (“BioCryst”) and **MDCP, LLC**, a Delaware limited liability company (“Peramivir SPE”, together with BioCryst and any other Person that joins this agreement as a Grantor, each a “Grantor” and collectively, the “Grantors”).

RECITALS

A. The Lenders have agreed to make certain advances of money and to extend certain financial accommodation to the Grantors (the “Credit Extensions”) in the amounts and manner set forth in that certain Credit and Security Agreement, by and between Agent, the Lenders and Grantor dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein are used as defined in the Credit Agreement). The Lenders are willing to make the Credit Extensions to the Grantors, but only upon the condition, among others, that the Grantors shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of the Grantors under the Credit Agreement.

B. Pursuant to the terms of the Credit Agreement, each Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of such Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Credit Agreement, each Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Credit Agreement, each Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of such Grantor’s right, title and interest in, to and under its intellectual property (except to the extent constituting Excluded Property) (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to such Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the

same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.


This security interest is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Credit Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Credit Agreement and the other Financing Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Credit Agreement or any of the Financing Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Credit Agreement or any of the other Financing Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.

[Signature page follows.]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

BIOCRIST PHARMACEUTICALS, INC.

By:  (SEAL)
Name: Jon P. Stonehouse
Title: President and Chief Executive Officer

MDCP, LLC

By:  (SEAL)
Name: Alan Buena
Title: Vice President & Secretary

Address:

BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd, Suite 200
Durham, NC 27703
Attn: Alan Buena
Facsimile: 919-859-1314
E-Mail: abuena@biocryst.com

AGENT:

MIDCAP FINANCIAL TRUST

**By: Apollo Capital Management, L.P.,
its investment manager**

**By: Apollo Capital Management GP, LLC,
its general partner**


By:  (SEAL)
Name: Maurice Amsellem
Title: Authorized Signatory

EXHIBIT A

Copyrights

Description

Registration/
Application
Number

Registration/
Application
Date

None.

EXHIBIT B

Summary of US Patents and Applications in BioCryst Patent Estate - September 14, 2016

Borrower that is Owner of IP¹	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	6,562,861	12/17/1998	12/17/2018
BioCryst	Antiviral Treatments	Patent	8,778,997	02/12/2007*	05/07/2027
BioCryst	Antiviral Treatments	Patent	14/313,738	02/12/2007*	02/12/2027
BioCryst	Cyclopentane and Cyclopentene Compounds and Use for Detecting Influenza Virus	Patent	6,503,745	11/05/1999	11/05/2019
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	Patent	6,576,786	06/09/2000*	06/09/2020
BioCryst	Process for Preparing (-)-(1S,4R) N-Protected 4-Amino-2-Cyclopentene-1-Carboxylate Esters	Patent	6,495,711	06/09/2000*	06/09/2020
BioCryst	Preparation of Substituted Cyclopentane and Cyclopentene Compounds and Certain Intermediates	Patent	6,762,316	06/28/2000	06/28/2020
BioCryst	Substituted Cyclopentane Compounds Useful as Neuraminidase Inhibitors	Patent	6,410,594	06/13/1997	06/13/2017
BioCryst	Pyrrolidin-2-One Compounds and Their Use as Neuraminidase Inhibitors	Patent	6,509,359	09/17/1998	09/17/2018
BioCryst	Substituted Pyrrolidine Compounds Useful as Neuraminidase Inhibitors	Patent	6,518,299	10/20/2000*	10/20/2020
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	5,985,848	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,066,722	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,228,847	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,492,347	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,803,455	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	7,211,653	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	7,390,890	10/14/1997*	10/14/2017
BioCryst*	Process for Preparing 2-Pyrrolidinyl-1H- Pyrrolo[3,2-d] Pyrimidine Inhibitors of Nucleoside Metabolism	Patent	6,693,193	04/07/2000	04/07/2020

EXHIBIT B

Summary of US Patents and Applications in BioCryst Patent Estate - September 14, 2016

Borrower that is Owner of IP¹	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date²	Projected Expiration Date³
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,022,852	04/07/2000	08/16/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,211,677	04/07/2000	04/07/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,405,297	04/07/2000	04/07/2020
BioCryst	Methods of Treating Hematologic Cancers	Patent	14/190,987	12/10/2008	12/10/2028
BioCryst*	5H-Pyrrrolo[3,2-d] Pyrimidine Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	7,553,839	08/21/2003	12/03/2023
BioCryst*	Fused Pyrimidines as Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	8,173,662	08/21/2003	09/01/2024
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrrolo[3,2-d]Pyrimidin-4-One	Patent	8,501,753	03/24/2010	03/24/2030
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Patent	8,853,224	09/07/2007	03/29/2029
BioCryst	Inhibiting T-Cell Proliferation	Patent	6,656,915	09/15/2000	09/15/2020
BioCryst	Inhibiting T-Cell Proliferation	Patent	6,660,719	12/17/2001*	02/10/2022
BioCryst	Process for the Preparation of Substituted Pyrrolidine Derivatives and Intermediates	Patent	7,230,119	08/25/2005*	10/10/2025
BioCryst	Carboxy Pyrrole, Process of Preparing and Use as Precursor	Patent	6,972,331	04/23/2003*	12/20/2023
BioCryst	Process for the Preparation of 9-Deazaguanine Derivatives	Patent	6,946,554	12/10/1996*	12/10/2016
BioCryst	Deazaguanine Analog, Preparation Thereof and Use Thereof	Patent	6,458,799	05/04/2001*	05/04/2021
BioCryst	Preparation of Deazaguanine Analog	Patent	6,780,993	02/19/2003*	02/19/2023
BioCryst	Antiviral Nucleoside Analogs	Patent	8,440,813	01/11/2008	11/16/2028
BioCryst	Therapeutic Furopyrimidines and Thienopyrimidines	Patent	7,429,571	10/28/2005	07/17/2026

EXHIBIT B

Summary of US Patents and Applications in BioCryst Patent Estate - September 14, 2016

Borrower that is Owner of IP¹	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date²	Projected Expiration Date³
BioCryst	Methods for the Preparation of 9-Deazapurine Derivatives	Patent	8,344,132	06/21/2006	03/28/2028
BioCryst	Hepatitis C Therapies	Patent	7,514,410	10/28/2005	10/14/2026
BioCryst	Hepatitis C Therapies	Patent	8,163,703	10/28/2005	10/14/2026
BioCryst	Nucleosides, Preparation Thereof and Use as Inhibitors of RNA Viral Polymerases	Patent	7,388,002	11/14/2002	12/31/2022
BioCryst	Tetrahydrofuro [3-4-D] Dioxolane Compounds for Use in the Treatment of Viral Infections and Cancer	Patent	8,242,085	05/08/2008	11/16/2028
BioCryst	Aza Nucleosides, Preparation Thereof and Use as Inhibitors of RNA Viral Polymerases	Patent	7,560,434	06/22/2005*	08/06/2026
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	13/879,110	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	14/531,471	10/14/2011	10/14/2031
BioCryst	Antiviral Azasugar-containing Nucleosides	Patent	14/441,762	11/18/2013	11/18/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Patent	14/395,355	04/17/2013	04/17/2033
BioCryst	Anti-Influenza Compositions and Methods	Patent	14/890,719	05/14/2014	05/14/2034
BioCryst	Compounds Useful in the Complement, Coagulat (sic) and Kallikrein Pathways and Methods for Their Preparation	Patent	6,653,340	06/03/1998	06/03/2018
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	6,699,994	10/22/2001	11/09/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	6,936,719	10/22/2001	11/09/2021
BioCryst	Compositions and Uses of Amidine Derivatives	Patent	PCT/US2015/046578	08/24/2015	08/24/2035
BioCryst	Compositions Comprising a Kallikrein Inhibitor	Patent	PCT/US2016/048456 ⁴	08/24/2016	08/24/2036
BioCryst	Method for Producing Amidine Derivatives	Patent	PCT/US2015/046582	08/24/2015	08/24/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	15/123,059 ⁵	03/09/2015	03/09/2035

EXHIBIT B

Summary of US Patents and Applications in BioCryst Patent Estate - September 14, 2016

NOTES:

- ¹ The asterisk (*) indicates "Licensee" status.
- ² Unless otherwise indicated, PCT filing date is listed. The asterisk (*) indicates earliest US Utility filing date for non-PCT- based applications.
- ³ Projected expiration dates extending beyond 20 years include PTA adjustments.
- ⁴ Not yet published, so unavailable to the public.
- ⁵ US national-stage of PCT/US2015/019535, which has published.

EXHIBIT B

Summary of Canadian Patents and Applications in BioCryst Patent Estate - September 20, 2016

Borrower that is Owner of IP¹	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date²	Projected Expiration Date
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	2315262	12/17/1998	12/17/2018
BioCryst	Intravenous Antiviral Treatments	Patent	2642260	02/12/2007	02/12/2027
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	2305760	10/14/1998	10/14/2018
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	2368095	04/07/2000	04/07/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	2634299	04/07/2000	04/07/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	2696826	04/07/2000	04/07/2020
BioCryst	Methods of Treating Hematologic Cancers	Patent	2708606	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	Patent	2881035	12/10/2008	12/10/2028
BioCryst*	5H-Pyrrolol[3,2-d] Pyrimidine Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	2496698	08/21/2003	08/21/2023
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrolol[3,2-d]Pyrimidin-4-One	Patent	2755950	03/24/2010	03/24/2030
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Patent	2662628	09/07/2007	09/07/2027
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	2813783	10/14/2011	10/14/2031
BioCryst	Antiviral Azasugar-containing Nucleosides	Patent	2890905	11/18/2013	11/18/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Patent	2870722	04/17/2013	04/17/2033
BioCryst	Anti-Influenza Compositions and Methods	Patent	2911424	05/14/2014	05/14/2034
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	2426430	10/22/2001	10/22/2021
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	2941380	03/09/2015	03/09/2035

NOTES:

¹ The asterisk (*) indicates "Licensee" status.

² PCT application filing date is listed.

EXHIBIT B

Summary of United Kingdom (GB), France (FR), and Germany (DE) Patents and Applications in BioCryst Patent Estate - September 20, 2016

Borrower that is Owner of IP¹	Name/Identifier of IP	Type of IP	Country	Patent or Application Number²	Filing Date³	Projected Expiration Date
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	GB, FR	1040094	12/17/1998	12/17/2018
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	DE	69840674.5	12/17/1998	12/17/2018
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	GB, FR	1023308	10/14/1998	10/14/2018
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	DE	69831499.9	10/14/1998	10/14/2018
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	GB, FR	1165564	04/07/2000	04/07/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	DE	60041757.3	04/07/2000	04/07/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	EP	9150953.9 (pending)	04/07/2000	04/07/2020
BioCryst	Methods of Treating Hematologic Cancers Using PNP Inhibitors such as Forodesine in Combination with Anti-CD20 Agents	Patent	EP	12177257.8 (pending)	12/10/2008	12/10/2028
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	GB, FR	1539783	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	DE	60336734.8	08/21/2003	08/21/2023
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrrol[3,2-d]Pyrimidin-4-One	Patent	GB, FR	2411394	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrrol[3,2-d]Pyrimidin-4-One	Patent	DE	602010018068.9	03/24/2010	03/24/2030
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Patent	GB, FR	2057165	09/07/2007	09/07/2027
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Patent	DE	602007013252.5	09/07/2007	09/07/2027
BioCryst	Compositions for Use in the Treatment of Viral	Patent	GB, FR	2627334	10/14/2011	10/14/2031

Confidential

EXHIBIT B

Borrower that is Owner of IP¹	Name/Identifier of IP	Type of IP	Country	Patent or Application Number²	Filing Date³	Projected Expiration Date
	Infections					
BioCryst	Compositions for Use in the Treatment of Viral Infections	Patent	DE	602011016176.8	10/14/2011	10/14/2031
BioCryst	Pyrrolopyrimidine Derivatives for Use in the Inhibition of Polymerase	Patent	EP	14198125.8 (pending)	10/14/2011	10/14/2031
BioCryst	Antiviral Azasugar-containing Nucleosides	Patent	EP	13855441.5 (pending)	11/18/2013	11/18/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Patent	EP	13778292.6 (pending)	04/17/2013	04/17/2033
BioCryst	Anti-Influenza Compositions and Methods	Patent	EP	14798158.3 (pending)	05/14/2014	05/14/2034
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	GB, FR	1383731 (pending)	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	DE	60139510.7	10/22/2001	10/22/2021
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	EP	To Be Assigned ⁴	03/09/2015	03/09/2035

NOTES:

¹ The asterisk (*) indicates "Licensee" status.

² All GB, FR, and DE patents are validations of an EP granted patent. GB and FR validations retain the EP patent number; DE validation numbers reflect the assigned German file number. Pending EP applications have GB, FR, and DE listed as designated states in which a future EP grant may be validated.

³ PCT application filing date is listed.

⁴ European national-stage filing of PCT/US2015/019535 (which has been published) has been authorized; EP application number is to be assigned.

EXHIBIT B

Summary of Japanese Patents and Applications in BioCryst Patent Estate - September 20, 2016

Borrower that is Owner of IP¹	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	4102022	12/17/1998	10/02/2020
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	5118502	12/17/1998	12/17/2018
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	5709688	12/17/1998	12/17/2018
BioCryst	Intravenous Antiviral Treatments	Patent	2013-174479	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Patent	2015-137495	02/12/2007	02/12/2027
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	Patent	4262920	06/09/2000	05/02/2021
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	Patent	4597237	06/09/2000	06/09/2020
BioCryst	Process for Preparing (-)-(1S,4R) N-Protected 4-Amino-2-Cyclopentene-1-Carboxylate Esters	Patent	4532801	06/09/2000	06/09/2020
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	4451983	10/14/1998	10/14/2018
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	4430247	04/07/2000	04/07/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	5070237	04/07/2000	04/07/2020
BioCryst	Methods of Treating Hematologic Cancers	Patent	5543362	12/10/2008	12/10/2028
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	4682314	08/21/2003	08/21/2023
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Patent	5766687	03/24/2010	03/24/2030
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Patent	5388067	09/07/2007	09/07/2027
BioCryst	Hepatitis C Therapies	Patent	5107228	10/28/2005	10/28/2025
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	5902698	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	2016-46875	10/14/2011	10/14/2031
BioCryst	Antiviral Azasugar-containing Nucleosides	Patent	2015-542870	11/18/2013	11/18/2033

Confidential

EXHIBIT B

Borrower that is Owner of IP¹	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date²	Projected Expiration Date³
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Patent	2015-507145	04/17/2013	04/17/2033
BioCryst	Anti-Influenza Compositions and Methods	Patent	2016-514060	05/14/2014	05/14/2034
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	4342178	10/22/2001	10/22/2021
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	Not Yet Available ⁴	03/09/2015	03/09/2035

NOTES:

¹ The asterisk (*) indicates "Licensee" status.

² PCT application filing date is listed.

³ Projected expiration dates extending beyond 20 years include PTE adjustments.

⁴ Japanese national-stage of PCT/US2015/019535, which has published; the Japanese application number is not yet available.

EXHIBIT C

Summary of Trademark Registrations and Applications in BioCryst Estate – September 20, 2016

Borrower that is Owner of IP¹	Country	Name/Identifier of IP	Type of IP	Trademark Registration or Application Number	Filing Date	Expiration Date¹
BioCryst	US	BIOCRYST	Trademark	3,974,837	08/14/2007	06/07/2021
BioCryst	US	BIOCRYST	Trademark	4,096,431	08/14/2007	02/07/2022
BioCryst	US	BIOCRYST LOGO	Trademark	3,966,596	08/14/2007	05/24/2021
BioCryst	US	BIOCRYST LOGO	Trademark	86-461,211	11/21/2014	To Be Determined
BioCryst	US	BIOCRYST PHARMACEUTICALS, INC	Trademark	2,902,002	06/11/2002	11/09/2024
BioCryst	US	BIOCRYST PHARMACEUTICALS, INC	Trademark	3,974,836	08/14/2007	06/07/2021
BioCryst	US	DESIGN, OPTIMIZE, DELIVER.	Trademark	4,074,214	05/19/2011	12/20/2021
BioCryst	CA	BIOCRYST PHARMACEUTICALS, INC.	Trademark	To Be Determined	To Be Determined	To Be Determined
BioCryst	EU	BIOCRYST PHARMACEUTICALS, INC.	Trademark	2960995	12/04/2002	10/24/2022
BioCryst	JP	BIOCRYST PHARMACEUTICALS, INC.	Trademark	4721741	12/04/2002	10/24/2023

¹For US trademarks, 10-year date based on initial registration date or subsequent renewal date. Assumes "Declaration of Use under Section 8" is filed between the fifth and sixth year following registration. The filing of a combined "Declaration of Use and Application for Renewal under Sections 8 and 9" must be filed between the ninth and tenth year after registration, and every 10 years thereafter, to maintain mark beyond the initial 10-year expiration date.

EXHIBIT D

Mask Works

Description

Registration/
Application
Number

Registration/
Application
Date

None.